Immunocore Holdings (IMCR) EBT (2021 - 2026)
Immunocore Holdings (IMCR) posted EBT of $13.3 million for Q1 2026, up 184.03% sequentially from -$15.8 million in Q4 2025, and up 118.15% YoY from $6.1 million in Q1 2025.
Immunocore Holdings (IMCR) EBT (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported EBT for 6 years, with the latest figure at $13.3 million in Q1 2026.
- Quarterly EBT rose 118.15% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.9 million (up 47.69% YoY) and the FY2025 annual result came in at -$19.1 million, up 63.92% from the prior year.
- EBT grew to $13.3 million in Q1 2026 per IMCR's latest filing, from -$15.8 million in the prior quarter.
- Over five years, EBT peaked at $13.3 million in Q1 2026 and troughed at -$27.4 million in Q4 2022.
- A 5-year average of -$10.2 million and a median of -$13.0 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT surged 733.52% in 2024, then plunged 95.01% in 2025.
- Over 5 years, EBT stood at -$27.4 million in 2022, then climbed by 6.33% to -$25.6 million in 2023, then advanced by 3.2% to -$24.8 million in 2024, then jumped by 36.37% to -$15.8 million in 2025, then soared by 184.03% to $13.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered $13.3 million, -$15.8 million, and $304000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Immunocore Holdings | 1.76 Bn | 880.92 Mn | 114.84 Mn | -514,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -514,000.00 |
| Mar 31, 2026 | 13.27 Mn |
| Dec 31, 2025 | -15.79 Mn |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | -9.69 Mn |
| Mar 31, 2025 | 6.08 Mn |
| Dec 31, 2024 | -24.82 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | -10.13 Mn |
| Mar 31, 2024 | -24.08 Mn |
| Dec 31, 2023 | -25.64 Mn |
| Sep 30, 2023 | 731,000.00 |
| Jun 30, 2023 | -16.82 Mn |
| Mar 31, 2023 | -19.16 Mn |
| Dec 31, 2022 | -27.37 Mn |
| Sep 30, 2022 | 5.87 Mn |
| Jun 30, 2022 | -22.39 Mn |
| Dec 31, 2021 | -52.81 Mn |
| Sep 30, 2021 | -44.47 Mn |